GE HealthCare Technologies (GEHC) Valuation Check As Earnings Near And Allia Moveo Launch Gains Attention

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide.

GE HealthCare Technologies (GEHC) heads into its upcoming earnings report with attention on two fronts: the expected 5.3% revenue growth to US$5.60b and fresh regulatory milestones for its Allia Moveo imaging system.

See our latest analysis for GE HealthCare Technologies.

Despite a stream of product and partnership updates, including the Allia Moveo clearances and the new anesthesia collaboration with U.S. Anesthesia Partners, the share price has slipped recently, with a 30 day share price return of 4.88% and a 1 year total shareholder return of 9.21%. The 3 year total shareholder return of 10.52% points to steadier long term progress.

If the upcoming earnings and product milestones have your attention, it could be a good moment to broaden your watchlist and use healthcare stocks as potential comparisons.

With GE HealthCare shares down 4.9% over the past month and trading below both analyst targets and some intrinsic estimates, the key question is whether this reflects a genuine opportunity or a market that has already priced in future growth.

The most followed narrative pegs GE HealthCare Technologies’ fair value at $92 per share compared with the last close at $78.78, putting its long term earnings and cash flow assumptions in the spotlight.

The pipeline of new high impact products, like Radiopharmaceuticals, Total Body PET, and Photon Counting CT, is anticipated to drive future revenue growth and potentially improve margins.

Read the complete narrative.

Curious what sits behind that $92 figure and the implied discount rate? The narrative leans heavily on steady top line growth, firm margins and a future earnings multiple that contrasts with today. It can be useful to see how those moving parts are combined and what they imply for profit power a few years out.

Result: Fair Value of $92 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, there is still real execution risk if tariffs, China related regulatory changes, or competitive product launches hit margins and slow the earnings path analysts expect.

Find out about the key risks to this GE HealthCare Technologies narrative.

If you look at the numbers and story and come to a different conclusion, or simply prefer your own work, you can put together a full narrative in just a few minutes with Do it your way.